All posts by medical

Hoxton Farms Bags US$3.75M To Bring Back Fat By Cultivating It From Animal Cells – Green Queen Media

London-based biotech startup Hoxton Farms has raised 2.7 million (approx. US$3.75 million) in a seed funding round for its cultivated fat technology. Using cell biology and mathematical modelling, the company grows a slaughter-free and sustainable better kind of fat directly from animal cells in bioreactors. Hoxton Farms says their cultivated fat ingredients will help elevate the sensory and functional properties of alternative proteins.

Hoxton Farms has announced a 2.7 million (approx. US$3.75 million) seed funding round led by San Francisco-based venture capital firm Founders Fund created by Peter Thiel, with participation from Backed, Presight Capital, CPT Capital and the dedicated alternative protein rolling fund on AngelList, Sustainable Food Ventures (SFV). Several angel investors also joined the seed round.

The London-headquartered biotech says that the capital will go towards expanding its interdisciplinary science team in their new lab in Hoxton, where it will continue developing its cultivated animal fat production platform.

Our mathematical approach drives everything we do at Hoxton Farms. We simulate the entire process computationally, from biopsy to bacon.

It plans to use its proprietary computational models to reduce the cost of manufacturing its purified animal fat in bioreactors, with the aim of building customer partnerships to supply its product to the alternative protein industry, starting with plant-based meat firms who are looking for better-tasting alternatives to plant oils.

Our mathematical approach drives everything we do at Hoxton Farms. We simulate the entire process computationally, from biopsy to bacon. This digital twin allows us to optimise every raw input in parallel, massively improving the cost-efficiency and performance of our cultivated fat for our customers, explained Ed Steele, co-founder of Hoxton Farms.

Hoxton Farms technology is aimed squarely at solving the challenge of finding low-cost, effective yet sustainable alternatives to traditional animal fat often described as the crucial ingredient in meat that gives the sensory experience that consumers crave. Cultivated animal fat, which is grown directly from the cells of animals, would also offer the functional textural, cooking qualities and appearance that alternative proteins producers have struggled to replicate using plant-based oils and fats.

Cultivated fat is the hero ingredient for meat alternatives, and it will solve a huge problem in this growing industry. We believe the future of meat alternatives will be a blend of plant-based protein and cultivated fat.

We want to bring back fat: its the single most important ingredient in the meat that we eat. The technology were developing will allow us to customise fat for any application and were making it healthier too, said Dr. Max Jamilly, co-founder of Hoxton Farms.

Cultivated fat is the hero ingredient for meat alternatives, and it will solve a huge problem in this growing industry. We believe the future of meat alternatives will be a blend of plant-based protein and cultivated fat.

Commenting on the decision to back Hoxton Farms, Eric Scott, principal at leading investor Founders Fund, said: The market for plant-based meat has exploded in recent years, especially during the pandemic. But plant-based meat has a long way to go and thats because its missing out on real cell-based animal fat.

The teams ability to tailor the precise sensory and functional properties of fat allows them to produce exactly what their customers need. Hoxton Farms has the potential to change an industry, Scott continued.

Plant-based meat has a long way to go and thats because its missing out on real cell-based animal fat.

While the number of startups educated to offering solutions to animal fats remains small, Hoxton Farms is by no means alone. Belgian B2B startup Peace of Meat, for instance, produces cultivated fat and texturing ingredients and has recently been bought out by Israeli cultured meat firm Meat-Tech 3D as part of its commercialisation strategy to launch hybrid alternative meats made from both plant and cell-based ingredients on the market.

Another food tech, Cubiq Foods, based in Barcelona, is creating cell-based fats that are high in omega-3 fatty acids. According to some reports, Cubiq Foods are already in talks with cultivated companies such as Mosa Meat for a potential collaboration.

Motif FoodWorks, on the other hand, are aiming to create a plant-based fat that has the attributes of animal-derived fats, which will help elevate the taste, texture and appearance of vegan meat and dairy alternatives.

Lead image courtesy of Hoxton Farms.

View original post here:
Hoxton Farms Bags US$3.75M To Bring Back Fat By Cultivating It From Animal Cells - Green Queen Media

Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells – BioSpace

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells.

The financial terms of the partnership include up to $760 million of development, regulatory, and sales milestones from Cytovia to Cellectis for the first 5 TALEN gene-edited iPSC-derived NK products (partnership products). Cellectis will also receive single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds.

We are excited to collaborate with Cellectis, a gene-editing pioneer and leader in the development of gene-edited allogeneic cancer therapies, to further accelerate Cytovias NK cell programs, said Dr. Daniel Teper, Chairman & CEO of Cytovia Therapeutics. Cellectis has a deep understanding and proven expertise in gene-edited cell therapies, and their gene editing technology, TALEN, will yield NK and CAR-NK treatments with improved potency, persistence, and safety for a variety of cancers, including solid tumors. We look forward to leveraging Cellectis insights and experience to help move Cytovias CAR-NKs into clinical trials by 2022.

Cellectis will develop custom TALEN, which Cytovia will use to edit iPSCs. Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis is granting Cytovia a worldwide license to its TALEN gene-editing technology, enabling Cytovia to modify NK cells addressing multiple gene targets for therapeutic use in several cancer indications.

We are thrilled to partner with Cytovia, a pioneer in the development of NK cells derived from iPSCs, said Dr. Andr Choulika, CEO of Cellectis. We are looking forward to this collaboration and the opportunity to further expand the potency of our proprietary TALEN gene-editing technology to iPSCs and CAR-NKs. Down the road, this collaboration should allow for NK cell therapies to be made available to cancer patients, which is very much in line with Cellectis mission to provide life-saving product candidates to address unmet patient needs in this field.

About CellectisCellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit http://www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN is a registered trademark owned by Cellectis.

About Cytovia TherapeuticsCytovia Therapeutics Inc. is a biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company is establishing R&D and GMP manufacturing operations in the greater Boston area and partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, INSERM, and CytoImmune Therapeutics.Learn more at http://www.cytoviatx.com and follow Cytovia Therapeutics on Social Media (Facebook, LinkedIn, Twitter, and Youtube).

About Gene-Edited, iPSC-derived NK CellsChimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). In addition, CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent innovative developments with the induced pluripotent stem cell (iPSC)-derived CAR-NKs, an innovative technology, allow large quantities of true off-the-shelf, homogeneous genetically modified CAR NK cells to be produced from a gene-edited iPSC master cell bank, and thus hold promise to expand access to cell therapy for many patients.

For further information, please contact:

Cellectis Media contacts:Margaret Gandolfo, Communications Manager, 646-628-0300, margaret.gandolfo@cellectis.comConor McGoldrick, Zeno Group, Assistant Account Executive, 914-355-0927, Conor.Mcgoldrick@zenogroup.com

Cellectis IR contact:Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Cytovia Investor Relations contact: Anna Baran-DjokovicVP of Investor Relations646-355-1787anna@cytoviatx.com

Cytovia Media contact: Chris MaggosLifeSci Advisors+41 79 367 6254chris@lifesciadvisors.com

Disclaimer

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, believe, expected, forward looking, promising and will, or the negative of these and similar expressions. These forward-looking statements, are based on our managements current expectations and assumptions and on information currently available to management. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

PDF available at: http://ml.globenewswire.com/Resource/Download/c6bbee7d-f56e-400c-a6a4-28586a9e4851

Read the rest here:
Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells - BioSpace

Research Associate in Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 246711 – Times Higher Education (THE)

Job descriptionThe Centre for Stem Cells & Regenerative Medicine is located in Guys Hospital.It is internationally recognized for research on adult and pluripotent stem cells and is a focus for cutting-edge stem cell research currently taking place across the College and its partner NHS trusts, as part of Kings Health Partners. Through the Centre, Kings aims to drive collaboration between scientists and clinicians to translate the potential of stem cells into clinical reality for patients.Applications are invited for a postdoctoral researcher funded as part of the PIs Wellcome Clinical Fellowship, and will work with a dynamic group of scientists focussed on reproductive biology, early embryonic development and the causes of infertility. The post holder will contribute to the regenerative medicine theme and will be involved in the generation and processing of single cell experiments using a variety of techniques.This is an exciting opportunity following our recent work (Sangrithi et al. 2017, Dev Cell & Lau et al. 2020, Dev Cell). The project aims to discover the function of genes on the X-chromosome in male germline stem cells (spermatogonia) and their role in idiopathic and sex chromosome aneuploidy associated infertility. We aim to understand physiological gene regulatory networks functional in spermatogonial stem cells using a combination of single-cell methods, to explain how perturbation in X-gene dosage in SSCs may cause infertility. The postholder will also identify and validate candidate disease bio-markers.This post will be offered on an a fixed-term contract until 05/04/2026This is a full-time post - 100% full time equivalent

Key responsibilities Carry out world class research. Are adept at working in a wet lab setting with experience in designing and executing experiments. Familiarity in single cell work nucleic acid manipulation is desirable Communicate results effectively in writing and orally Contribute to publications arising from the research projects Keep clear and up-to-date records of work Attend and present at seminars, journal clubs and conferences Contribute to collaborative atmosphere of the department Share skills by training others Comply with all relevant safety legislation to ensure a safe working environment Take part in public engagement activities To support grant writing, for maintaining the continual research in this domain, e.g. Fellowships Post holder will be expected to plan and prioritise their own workload, with competing and shifting priorities under pressure of deadlinesThe above list of responsibilities may not be exhaustive, and the post holder will be required to undertake such tasks and responsibilities as may reasonably be expected within the scope and grading of the post.

Skills, knowledge, and experience

Essential criteria PhD awarded in the biological sciences Excellent general knowledge of molecular biology Knowledge of cell biology Knowledge of flow cytometry Relevant postdoctoral experience Experience in a molecular biology research lab Excellent record keeping / attention to detail Organized and systematic approach to research Pro-active, enthusiastic, positive attitude Self-motivated, with the ability to work under pressure & to meet deadlines Keen interest in infertility and regenerative medicine Ability to think strategically

Desirable criteria Understanding of the biology of germ cells and embryo development Previous experience in working with the laboratory mouse ES cell culture experience General knowledge of computational tools for single cell RNAseq Ability to make collaborative and independent decisions*Please note that this is a PhD level role but candidates who have submitted their thesis and are awaiting award of their PhDs will be considered. In these circumstances the appointment will be made at Grade 5, spine point 30 with the title of Research Assistant. Upon confirmation of the award of the PhD, the job title will become Research Associate and the salary will increase to Grade 6.Further informationABOUT THE SCHOOLThe School of Basic & Medical Biosciences is led by Professor Mathias Gautel and comprises five departments with a wide range of expertise and interests. Using a bench to bedside approach, the School aims to answer fundamental questions about biology in health and disease and apply this to the development of new and innovative clinical practise, alongside providing a rigorous academic programme for students.DepartmentsThe Centre for Human & Applied Physiological Sciences (CHAPS) uses an integrative and translational research approach focusing on fundamental questions about human physiological function in health and disease to explore 3 research themes: skeletal muscle & aging, sensory-motor control & pain and aerospace & extreme environment adaptation.The Centre for Stem Cells & Regenerative Medicine focuses on cutting-edge stem cell research, how stem cells interact with their local environment and how these interactions are important for developing effective cell therapies in the clinic.The Department of Medical & Molecular Genetics uses cutting-edge technologies and analysis techniques to explore the mechanistic basis of disease, improve diagnostics and understand the epigenetic mechanisms of gene regulation and RNA processing, working from whole population level to complex and rare disease genomesThe Randall Centre of Cell & Molecular Biophysics takes a multi-disciplinary approach at the interface of Biological and Physical Sciences to explore the underlying mechanisms behind common diseases.St Johns Institute of Dermatology seeks to improve the diagnosis and management of severe skin diseases, through a better understanding of the basic pathogenetic mechanisms that cause and sustain these conditions focussing on cutaneous oncology, genetic skin disorders, inflammatory & autoimmune skin disorders, and photomedicine.About the Department of Centre for Stem Cells & Regenerative MedicineThe Centre for Stem Cells & Regenerative Medicine is led by Professor Fiona Watt, whos laboratory comprises approximately 30 research staff and visiting scientists and is internationally recognised for research on adult and pluripotent stem cells. Along with Professor Watts group there are nine other research groups operating at the Centre, bringing the total number of staff to approximately 80 people.Research at the Centre is focused on how stem cells interact with their local environment, or niche. We believe that an understanding of these interactions is important for developing effective cell therapies in the clinic. Located on the Guys Hospital campus, the Centre acts as a focus for cutting-edge stem cell research taking place across the College and its partner NHS Trusts, as part of Kings Health Partners. To facilitate collaborations within Kings and with external partners, we have opened a Stem Cell Hotel where researchers can access specialist equipment and technical support to study stem cell behaviour at single cell resolution. We also host an international seminar series and run the Stem Cells @ Lunch seminar series to share ideas and unpublished data. Our researchers are committed to public engagement and take part in diverse outreach events.Detailed information about the Centre for Stem Cells & Regenerative medicine can be found in the link below:http://www.kcl.ac.uk/lsm/research/divisions/gmm/departments/stemcells/index.aspx

Continued here:
Research Associate in Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 246711 - Times Higher Education (THE)

Study seeks to identify biological markers that predict mesothelioma response to treatment – Baylor College of Medicine News

The National Cancer Institute (NCI) has granted a $2.5 million, five-year R37 MERIT Award to Dr. Bryan Burt, associate professor of surgery and chief of the Division of General Thoracic Surgery, for his research project titled, Proteomic Determinants of Response to Checkpoint Blockade in Malignant Pleural Mesothelioma.

Malignant pleural mesothelioma (MPM) is a fatal cancer of the lining of the lungs that has defeated standard therapies for decades. In recent years, emerging clinical data has shown that treatment with a form of immunotherapy called immune checkpoint inhibitors (ICIs) results in meaningful extension of life in half of patients with MPM, but is associated with immune-related side effects, Burt said.

The goal of this study is to develop a clinically relevant test that would enable physicians to determine whether a patient would be most likely or less likely to respond to ICIs before the patient gets treatment, saving those less likely to respond from immune-related adverse events.

We want to be able to predict not only who is going to respond, but also the strength of the response.

In other words, whether the tumor will completely or partially shrink or just remain stable for long periods of time, which is important too, Burt said. We hope to design a test that would allow us to predict those possible outcomes.

To develop the test, Burt is taking a closer look inside MPM tissues.

Preliminary data collected retrospectively showed that the tumors of patients who respond to ICIs tend to have a certain immune cell composition, which is quite complex, Burt said.

We developed a technique to analyze the presence of about 30 different cell types in a very small bit of a tumor sample.

Burt also is looking at the architecture of the tissue samples. In addition to determining how many cells there are of each type, we also study tissue architecture to see how these cells are organized in the tumor. Are they close to blood vessels? Are they close to each other? Our preliminary data showed that tissue immune cell architecture in the tumor also predicts response to treatment, Burt said.

The study also seeks to better understand the biological mechanism supporting the responders.

Our preliminary data suggested that MPMs with high levels of neoantigens, new tumor surface molecules that can warn the immune system of the presence of the tumor, is not the only requirement for responding to ICIs, Burt said. Its also important to take into consideration molecules called MHC, which present neoantigens to the immune system and facilitate the stimulation of the soldier immune cells. We have found that when both neoantigens and certain MHC molecules are there, the patient responds well to the therapy.

Burt hopes that the analyses of tumor neoantigens and HLA molecules can be developed into a test to predict response to ICIs, but also that it will help understand neoantigen biology that could be applicable to other tumors as well.

We anticipate that after this study supported by the R37 MERIT Award we will be able to use both cellular organization and neoantigen:MHC concordance to predict response to ICIs, Burt said.

It will then be time for a clinical trial to conduct a rigorous prospective evaluation in which treatment depends on the results of the test.

Burts research submission to the NCI as an R01 application received a score within the NCI pay line for experienced investigators and was thus converted to an R37 MERIT Award. This award enables National Institutes of Health institutes, such as the NCI, to give investigators with stellar records of research accomplishment a five-year award with the possibility of extension for additional years without undergoing another Integrated Review Groups (IRG) peer review. Burts five-year award has an opportunity for an extension of up to two additional years. The plan is to conduct the study between 2021 and 2028.

By Ana Mara Rodrguez, Ph.D.

Read more here:
Study seeks to identify biological markers that predict mesothelioma response to treatment - Baylor College of Medicine News

Nuclear TEAD4 with SIX1 Overexpression is an Independent Prognostic Ma | CMAR – Dove Medical Press

Tong Yu,1,2,* Jinglue Song,1,2,* Hui Zhou,1,2 Tingyu Wu,1,2 Zhonglin Liang,1,2 Peng Du,1,2 Chen-Ying Liu,1,2 Guanghui Wang,3 Long Cui,1,2 Yun Liu1,2

1Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Peoples Republic of China; 2Shanghai Colorectal Cancer Research Center, Shanghai, Peoples Republic of China; 3Guizhou Provincial Peoples Hospital, Guizhou, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Yun Liu Tel + 86-021-25078825Email liuyun@xinhuamed.com.cnGuanghui Wang Email wangguanghui0625@163.com

Introduction: Stage IIII colorectal cancer patients are under risk of tumor recurrence and metachronous metastasis after radical surgery. An increased expression of transcription factor TEAD4 is associated with epithelial-mesenchymal transition, metastasis and poor prognosis in colorectal cancer. However, the mechanistic role of TEAD4 in driving colon cancer progression and its prognostic value in early stage of CRC remains unclear.Methods: In this study, the regulation, function and prognostic significance of TEAD4 and its new direct target gene SIX1 in CRC progression were evaluated using human tissues, molecular and cell biology.Results: We show that TEAD4 directly upregulates the expression of SIX1 at transcriptional level in CRC cells, establishing that SIX1 is a new direct target gene of TEAD4. TEAD4 promotes EMT and cell migration of CRC cells, while SIX1 knockdown attenuates this effect and SIX1 overexpression enhances this effect, indicating that SIX1 mediates the function of TEAD4 in promoting cell migration in CRC cells. Clinically, nuclear TEAD4, overexpression of SIX1 and nuclear TEAD4 with SIX1 overexpression predict poor prognosis in CRC patients.Discussion: Our study identifies TEAD4-SIX1-CDH1 form a novel signaling axis, which contributes to CRC progression, and its aberrant expression and activation predicts poor prognostic for CRC patients in stage IIII.

Keywords: colorectal cancer, TEAD4, SIX1, hippo pathway

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Nuclear TEAD4 with SIX1 Overexpression is an Independent Prognostic Ma | CMAR - Dove Medical Press

Cell Biology Cloud Computing Market 2026 | Future Growth and Opportunities with Dazzling Key Players Accenture, Amazon Web Services, Benchling, Cisco…

The Cell Biology Cloud Computing Market study added by ResearchMoz, exhibits a comprehensive analysis of the growth trends present in the global business scenario. The study further presents conclusive data referring to the commercialization aspects, industry size and profit estimation of the market.

Cell Biology Cloud Computing Market analysis on global market is a thorough study that offers a select combination of skillful market realities. The study shows changing market trends as well as the size of individual segments in this market. This report mentions various top players involved in this market. Analysis of the Global Cell Biology Cloud Computing Market begins with a market-based outline and underlines the current information on the global market, complemented by data on the current situation.

Get Sample Copy of this Report @

https://www.researchmoz.us/enquiry.php?type=S&repid=2655551

Key Vendors are Involved in Industry:

Accenture, Amazon Web Services, Benchling, Cisco Systems, Dell Emc, IBM, DXC Technology, Oracle, ScaleMatrix, IPERION, NovelBio

Cell Biology Cloud Computing Breakdown Data by TypePublic Cloud ComputingPrivate Cloud ComputingHybrid Cloud ComputingCell Biology Cloud Computing Breakdown Data by ApplicationGenomicsDiagnosticsClinical TrialsPharma ManufacturingOthers

Market predictions for possible growth opportunities have been mentioned clearly. This report is a detailed description of the Cell Biology Cloud Computing Market sector which presents a blend of research expertise and business strategies. It also projects market trends along with the increasing scope for the individual sectors.

Insightful case studies from some significant industry experts have also been encapsulated. Various factors responsible for market growth have been examined at length. Cell Biology Cloud Computing Market report also offers analytical data on the bargaining power of vendors and buyers.

Get Flat 20% Discount On Latest Publish Report@:

https://www.researchmoz.us/enquiry.php?type=D&repid=2655551

The global Cell Biology Cloud Computing market report also indicates a narrowed decisive summary of the global market. Along with this, multiple factors which have affected the advancement and improvement in a positive as well as negative manner are also studied in the report. On the contrary, the various factors which will be acting as the opportunities for the development and growth of the market in the forecasted period are also mentioned.

The Cell Biology Cloud Computing Market report focuses on the requirements of the clients from several global Market regions such as North America, Latin America, Asia-Pacific, Europe, and India.

Benefits of Cell Biology Cloud Computing Market:

Table of Content:

Cell Biology Cloud Computing Market Research Report 2020-2026

Chapter 1: Industry Overview

Chapter 2: Cell Biology Cloud Computing Market International and Market Analysis

Chapter 3: Environment Analysis of Cell Biology Cloud Computing

Chapter 4: Analysis of Revenue by Classifications

Chapter 5: Analysis of Market Revenue Status

Chapter 6: Analysis of Revenue by Regions and Applications

Chapter 7: Analysis of Cell Biology Cloud Computing Market Key Manufacturers

Chapter 8: Sales Price and Gross Margin Analysis

Enquiry Before Buying:

https://www.researchmoz.us/enquiry.php?type=E&repid=2655551

*Dont miss out on business opportunities in Cell Biology Cloud Computing Market. Speak to our analyst and gain crucial industry insights that will help your business grow and If you have any special requirements, please let us know and we will offer you the report as you want.

For More Information Kindly Contact:

ResearchMoz

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: sales@researchmoz.us

Media Release: https://www.researchmoz.us/pressrelease

Follow Me On: http://amarketresearchreports.blogspot.com/

Read more here:
Cell Biology Cloud Computing Market 2026 | Future Growth and Opportunities with Dazzling Key Players Accenture, Amazon Web Services, Benchling, Cisco...

2020 Outlook on the Global Singlecell Technology Industry – Market Size was Over $800 Million in 2019 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Singlecell Technology Market Landscape 2020" report has been added to ResearchAndMarkets.com's offering.

The global single cell technology (SCT) market has emerged since 2014. There are over 43 companies with various 49 SCT products commercialized worldwide, and over 15 pre-commerce-stage startups are lined up and keep increasing. The market size is over $800 M in 2019, at a CAGR of ~24%.

The market is expected to grow significantly by the growing awareness of the single cell projects among biology communities, the growth of precision medicine and diagnostic industry, the antibody therapeutic drug development, the entry of new players, etc.

However, the high cost of the equipment, the requirement of in-person demo, various remaining technical challenges & defaults of the products that rushed into the market too early, and lack of interdisciplinary expertise on the customer sides could limit the market growth rates. Acquisitions and partnerships are actively seen as for most of the competitive technology industry.

The majority (~60%) of the market players are small-sized startup companies with under 100 employees, however, the market share is highly concentrated on four major companies (BD, 10x genomics, Fluidigm, and Berkeley light), yet this market share can change as the market is expanding and more new players are entering, more differentiation among players is expected.

Primarily, the SCT market has a complex market structure characterized by its wide range of technology mixtures and various types of users across various life science research fields. The general functionalities of the SCT are: single cell (SC) isolation, SC-sequencing, SC-protein analysis, or SC-focused manipulation. Among those, the first two category products (SC-isolation and SC-sequencing) account for ~72% of the market.

SCT can be applied in most of the life science application as it is defined by any biological science experimentation that handles and generate single cell resolution data. Stem cell research and cancer research are the fields of studies that have adapted SCT the most, and immunology and neurobiology also have a growing need in SCT. The market is categorized by the core technologies (11 categories) and by the applications (5 categories).

The core technology categories include conventional cell picking, limited dilution, FACS, and laser capture microdissection (LCM) technologies, but also novel technologies for automatic single cell picking, automatic single cell dispensing, microwell-based single cell isolation/analysis, microfluidic chip based-single cell analysis, droplet microfluidics-based, novel cytometry, and cell manipulation. The five market application categories include SC-isolation, SC-DNA/RNA sequencing, cell line development, protein or functional analysis, and drug discovery & diagnostics.

Companies Mentioned

Key Topics Covered:

Preface

Executive Summary

Part One: the Market and Strategy Perspectives

Chapter 1 Market Structure and Market Size

1.1 Market Structure

1.2 Market Size

1.3 Market's Dynamic Growth & Restraint Factors

Chapter 2 Projecting Strategic Plans

2.1 Strategic Moves by Current SCT Companies

2.2 Market Innovating Strategy

Part Two: Biology and Its Evolution- Market from the Customers Perspective

Chapter 3 Single Cell Biology by -Omics and Field of Study

3.1 Single Cell Biology: Physics and Engineering Meet Biology

3.2 Single Cell Biology by -Omics Fields

3.3 Single Cell Biology by Field of Studies

Chapter 4 Understanding the Customer and Their Workflow

4.1 Understand the Customer's Workflow

4.2 Understand the Customer Experience Cycle

Part Three: Market from the Technology Providers Perspective

Chapter 5 Market Segments by Technology

5.1 Overview

5.2 Manual Picking

5.3 Limited Dilution

5.4 FACS: Fluorescence Activated Cell Sorter

5.5 Laser Capture Microdissection (LCM)

5.6 Automatic Single Cell Pickers

5.7 Single Cell Dispensing

5.8 Microwell Based Single Cell Isolation

5.9 Microfluidics Chip-Based Single Cell Analysis

5.10 Droplet Microfluidics

5.11 New Type of Cytometry and Spectroscopy

5.12 Fluidics and Cell Manipulation

Chapter 6 Market Segments by Applications

6.1 Overview

6.2 SC-Dna and Rna Sequencing

6.3 Cell Line Development

6.4 Protein or Functional Analysis

6.5 Drug Discovery and Diagnostics

Chapter 7 Emerging Early Stage SCT Startup Companies

7.1 Emerging Early Stage SCT Startup Companies

or more information about this report visit https://www.researchandmarkets.com/r/6q7yf9

Link:
2020 Outlook on the Global Singlecell Technology Industry - Market Size was Over $800 Million in 2019 - ResearchAndMarkets.com - Business Wire

Taysha Gene Therapies Announces Formation of Independent Scientific Advisory Board – Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations, today announced the formation of an independent Scientific Advisory Board (SAB) that will work closely with senior management to advance the companys clinical development and commercialization efforts.

We are excited and privileged to have the opportunity to work with this cross-functional group of esteemed scientific and clinical thought leaders on initiatives from discovery, through pre-clinical and clinical development and commercialization, said Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha. They bring a wealth of knowledge in the development of gene therapy products and diseases of the CNS that will be invaluable as we advance our extensive pipeline of AAV-based gene therapies for the treatment of monogenic diseases of the CNS. Formalizing the SAB is an important accomplishment that will help position Taysha for sustained success as we further our R&D initiatives.

The SAB brings together the expertise of esteemed independent scientists and clinicians covering Tayshas key areas of research in monogenic diseases and gene therapy products. Members of the SAB will provide scientific review and guidance to the company around its R&D and related business activities.

Members of Tayshas SAB include:

Deborah Bilder, M.D., is an Associate Professor at the University of Utah in Educational Psychology, General Pediatrics, and Child Psychiatry. Her research interests include clinical trials, medications, and biologics that target rare genetic conditions and has authored over 45 peer-reviewed articles. She is the Principal Investigator for the Utah Registry of Autism and Developmental Disabilities and Co-Principal Investigator for the Utah site of the Centers for Disease Control and Preventions Autism and Developmental Disabilities Monitoring Network. Dr. Bilder is Co-Chair of the DAC Committee in psychiatry at the University of Utah and a consultant for the Utah Regional Education in Neurodevelopmental and Related Disabilities program. She has been awarded the Triple Board Program Teaching Award from the University of Utah Division of Child and Adolescent Psychiatry. She is a steering committee member for BioMarin Pharmaceutical Phase 3 Clinical Trial and also serves as a medical advisor for the Utah chapter of Make-a-Wish Foundation. Dr. Bilder earned her medical degree from Vanderbilt University.

Alan Boyd, B.Sc., M.B., Ch.B., FRSB, FFLM, FRCP, FFPM, is the CEO and Founder of Boyd Consultants and a fellow and Immediate Past-President of the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians, UK. Professor Boyd is also a Council Member and the Independent Clinician Trustee on the Board of the Academy of Medical Royal Colleges, UK. He is also an honorary professor at the University of Birmingham Medical School, in recognition of his expertise in medicine development. He has significant pharmaceutical industry experience and was the Head of Medical Research at AstraZeneca and the Research and Development Director at Ark Therapeutics Ltd, specializing in the development of gene therapy products. He is a graduate in biochemistry and medicine from the University of Birmingham, UK.

Wendy K. Chung, M.D., Ph.D., is a Kennedy Family Professor of Pediatrics in Medicine, Attending Physician in the Division of Molecular Genetics, Department of Pediatrics and Medicine, and the Director of Clinical Genetics, Clinical Cancer Genetics, and Precision Medicine Resource at the Irving Institute for Translational Research, all at Columbia University. Her research interests include spinal muscular atrophy, autism, and neurogenetics. Dr Chung has authored over 500 peer-reviewed articles and 75 textbook chapters and serves on the Editorial Board of Molecular Case Studies and The American Journal of Human Genetics. Dr Chung is the Director of Clinical Research at the Simons Foundation Autism Research Initiative (SFARI) and a member of the National Academy of Medicine. Dr. Chung earned her medical degree from Cornell University Medical College and her doctorate from Rockefeller University.

David P. Dimmock, M.D., is the Senior Medical Director of Rady Childrens Institute for Genomic Medicine. Dr. Dimmock is an expert in the field of clinical genomic medicine, the Principal Investigator on multiple clinical trials of novel therapeutics in rare metabolic diseases and an author of over 100 peer-reviewed articles, publications, chapters, books and reviews. He has been an invited advisor to the U.S. Food and Drug Administration in the Office of Orphan Diseases and has overseen regulatory submissions for whole genome sequencing devices. At the Center for Disease Control, he was a member of the Planning and Organizing Committee of NeXT-StoC to develop guidance to ensure analytic quality of next-generation sequencing tests. In addition, he was a member of the National Genomics Board UK and CLIAC NGS Guidelines Forum. He is a Scientific Advisory Board member for BioMarin Pharmaceuticals. Dr. Dimmock is a graduate from St. Georges, University of London.

Michael W. Lawlor, M.D., Ph.D., is a Professor of Pathology, Biomedical Engineering, Physiology, Cell Biology, Neurobiology, and Anatomy and the Associate Director of the Neuroscience Research Center at the Medical College of Wisconsin. He is a Board-Certified Anatomic Pathologist and Neuropathologist, and his research interests include pediatric muscle disease and gene therapy. Dr. Lawlor is an Editorial Board member of Muscle and Nerve and Journal of Neuropathology and Experimental Neurology. He is currently serving as an SAB member for Solid Biosciences in support of its gene therapy programs. Dr. Lawlor earned his medical degree and doctorate from Loyola University School of Medicine and his residency, fellowship, and postdoctoral training was completed at Massachusetts General Hospital and Boston Childrens Hospital in association with Harvard Medical School.

Gerald S. Lipshutz, M.D., M.S., is a Professor-in-Residence in the Departments of Surgery and Molecular and Medical Pharmacology, Surgical Director of the Pancreas/Auto-islet Transplant Program and Chairman of the Academic Medicine College at the David Geffen School of Medicine at University of California, Los Angeles. His clinical specialties and interests include liver and pancreas transplantation and gene and cell therapies for single-gene metabolic disorders of the liver. Dr. Lipshutz is a grant reviewer for the Wellcome Trust and the US National Institutes of Health where he is a standing member of the Gene and Drug Delivery (GDD) study section. He is a Principal Investigator at the UCLA Lipschutz Hepatic Regenerative Medical Laboratory and for several NIH-funded and industry-sponsored studies for gene therapies. He is author of over 70 peer-reviewed articles and is an Editorial Board member of Molecular Therapy - Methods and Clinical Development and Gene Therapy. Dr. Lipshutz earned his medical degree from the University of California, Los Angeles.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http://www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as anticipates, believes, expects, intends, projects, and future or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed. Forward-looking statements are based on managements current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (SEC) filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, which is available on the SECs website at http://www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

See the article here:
Taysha Gene Therapies Announces Formation of Independent Scientific Advisory Board - Business Wire

At Yale, new neuroscience institute to unravel the mysteries of cognition – Yale News

The human brain is the source and conduit of all ideas, beliefs, and dreams.

It drives us to produce art, literature, and science, to feel and describe love, to invent for survival and diversion alike.

Through it, we perceive, we wonder, we question: Why? How? What if?

Researchers at Yale University have been studying the brain for generations. Now, a new and historic philanthropic gift is launching an ambitious research enterprise devoted to the study of human cognition that will supercharge Yales neuroscience initiative and position the university to reveal the brain in its full, dynamic complexity.

The gift, made by Yale alumnus Joseph C. Tsai 86, 90 J.D., and his wife, Clara Wu Tsai, will establish the Wu Tsai Institute, a new kind of research organization that bridges the psychological, biological, and computational sciences. The Institute will pursue a mission to understand human cognition and explore human potential by sparking interdisciplinary inquiry. It will harness and amplify Yales strengths in neuroscience broadly defined, joining hundreds of researchers in a university-wide effort to understand the brain and mind at all levels from molecules and cells to circuits, systems, and behavior.

Research into the building blocks and emergent properties of the brain will address fundamental questions about human nature and potential: How do countless neurons and synapses transform sensations into perceptions, thoughts, and beliefs? What enables us to learn so much as young children, and can this be reawakened later in life? Why do we struggle to remember the past and pay attention to the present? Which cognitive capabilities are difficult for computers to mimic and why?

The answers to such questions offer the possibility of enlivening human experience, advancing mutual understanding, and improving society making education and organizations more effective, physical and mental health more durable, and technology more natural and supportive at work and home.

Understanding cognition is one of the greatest challenges in the history of science.

President Peter Salovey

Understanding cognition is one of the greatest challenges in the history of science, said Yale President Peter Salovey, a social psychologist and pioneer of the study of emotional intelligence. Thanks to the vision and generosity of Joe Tsai and Clara Wu Tsai, Yale will pursue a thrilling new approach to the intensive, long-term study of the brain and the wonders of the mind. This is a vast undertaking that advances Yale as a leader in scientific research, while promising insights that will improve life for people around the world.

Joe Tsai is co-founder and executive vice chairman of the global internet technology company Alibaba Group. Clara Wu Tsai, a former executive at American Express and Taobao Hong Kong, leads the family foundations work in supporting scientific research, economic mobility, social justice, and creativity in the arts. The Tsais are also owners of several professional sports franchises, including the Brooklyn Nets, New York Liberty, and San Diego Seals. Major global philanthropists and devoted Yale benefactors, the Tsais have made previous gifts establishing theTsai Center for Innovative Thinking at Yale (Tsai CITY), as well assupporting the Yale mens and womens lacrosse programs, the Department of Computer Science, and Yale Law School.

The worlds great universities are built to pursue consequential questions, and nothing is more foundational than understanding the mystery of the human brain, Joe Tsai said. Today, the science and technology community is obsessed with artificial intelligence, but how do we know if computers can outsmart humans if we do not fully appreciate our own cognitive capacities? Clara and I believe that Yale has the right combination of people, resources, and collaborative culture to lead to a better understanding of this big question.

Interdisciplinary collaboration is fundamental to success in the life sciences field, said Clara Wu Tsai. Our foundation is built on that very premise, and, in all of our efforts, Joe and I work to bring great scientists together across fields and areas of expertise.From the maturation of the mind and brain to the development of new cognitive computational models and the study of human behavior,scientists at the Wu Tsai Institute will be working on the very cutting edge of the cognitive sciences.

Yale starts from a position of strength and draws on a distinguished legacy of faculty in neuroscience, includingNobel Prize winners and National Academy of Sciences members who made discoveries that helped lay the biological and psychologicalfoundations of the field.

Today, about 140 Yale research groups are engaged in research related to neuroscience in departments throughout the Faculty of Arts and Sciences (e.g., linguistics; mathematics; molecular biophysics and biochemistry; molecular, cellular and developmental biology; philosophy; psychology; statistics and data science), School of Medicine (e.g., cell biology; cellular and molecular physiology; Child Study Center; genetics; neurology; neuroscience; neurosurgery; psychiatry), and School of Engineering & Applied Science (e.g., computer science; biomedical engineering; electrical engineering; mechanical engineering and materials science). The Wu Tsai Institute will unite these scholars in some cases physically and in all cases through shared resources and facilities while expanding their ranks. The Institute will recruit new faculty, staff, and students, and will drive collaboration through innovative programs and events in which rising and established experts from different disciplines influence and inspire each other, accelerating the pace of discovery.

Neuroscience is a special opportunity for Yale because we have many allied strengths already, said Provost Scott Strobel, a biochemist. By organizing ourselves in a way that links them to a common purpose, we can make huge leaps forward. The Wu Tsai Institute will enable discoveries that transcend disciplines, embodying our conviction that the greatest advances in science depend not only on penetrating subject-matter expertise, ingenuity, and perseverance, but also on the co-mingling and creative cooperation of experts to produce entirely new ways of thinking.

The Wu Tsai Institute will occupy space at 100 College St., a light-filled structure in a reborn area of downtown New Haven between Yales medical and central campuses that is being renovated to house offices, labs, and classrooms. The Institute will move into the building by fall 2022, along with the Department of Psychology from the Faculty of Arts and Sciences (FAS), the Department of Neuroscience from the School of Medicine, and colleagues from more than half a dozen other departments, facilitating interaction among researchers across the university and beyond.

Led by Yale psychologist and inaugural directorNicholas Turk-Browne, the Wu Tsai Institutes vision is uniquely interdisciplinary and cooperative.

The Institute will provide resources and incentives human, technological, social, and structural to make daring intellectual partnerships appealing and fruitful, he said. Whether sparked by a spontaneous remark in a common room, a question from left field after a talk, or a more intentional collaboration in which research groups co-design experiments from scratch, the success of the Institute in making headway on understanding human cognition requires more than business-as-usual: It requires bold, unorthodox scientific expeditions.

The Institute is organized with this guiding spirit in mind. Embedded within the Institutes global structure will be three cutting-edge academic centers. Approaching the common problem of cognition from different and complementary perspectives, the centers will provide local structure through whichnew laboratories, facilities, and services facilitate vanguard neuroscience research:

A defining feature of the Wu Tsai Institute is the interdependence of these centers, said Turk-Browne, who studies the interaction and development of fundamental cognitive processes in the human brain. The centers are not departments, he said, nor will they become silos within the Institute. Rather, the success of each will depend upon input from and collaboration with the others.

Scientific interest in the brain originated in the magic of the mind, he said. Neuroscience as a field then branched off into subfields studying the brain at different scales, using different tools and concepts, and affiliating with different neighboring disciplines. This has led to rapid progress in recent decades. Now is the time to reunite these subfields and together address the founding aspiration of neuroscience to reveal the inner workings of the mind through an integrated understanding of the brain. Achieving this integration across scales, tools, and disciplines with data science will enable powerful new theories and insights about what makes us human.

The Wu Tsai Institute will catalyze this integration and will provide a global framework, offering resources, programs, and activities that span the breadth of neuroscience and connected fields. It will allow Yale to recruit several world-class neuroscientists into endowed professorships, create an internal grant mechanism to encourage high-risk/high-reward ideas, begin a new independent postdoctoral fellowship program, expand dramatically the number of neuroscience-related graduate positions, and launch a paid internship program for undergraduates to inspire the next generation of scientists and scientifically minded citizens. These initiatives strive to connect the subfields of neuroscience through an executive committee of faculty leaders; a steering committee of stakeholders across the university; joint appointments spanning departments and schools; co-mentorship of students and postdocs; support for interdisciplinary research collaborations; and community-building workshops, retreats, and seminars. All activities will be guided and evaluated byGiovanna Guerrero-Medina,a member of the Institute staff dedicated to fostering diversity and excellence.

The creation of new initiatives provides an opportunity to confront historical and ongoing systemic inequities in neuroscience and to do better, she said. We will design programs and processes from the ground up to promoteequity and inclusionfor underrepresented groups across race, ethnicity, gender, sexual orientation, and ability.

The scientific ambitions of the Institute resonate with two of Yales fivemajor scientific priorities for the coming decade:neuroscience and integrative data science.

Data science brings a mathematical and computational toolkit that can be applied across scales and subfields of neuroscience, said John Lafferty, Yale data scientist and member of the executive committee. This provides a common language for talking about molecules and behavior in the same breath, for linking cellular activity to blood oxygenation. At the same time, few machine learning algorithms were designed for neuroscience data or with knowledge of key problems in the field, creating the opportunity for a new wave of approaches. The goal is not to recreate the brainin silicobut rather to learn principles behind how the brain works and to create algorithms that follow these strategies. This will create a computational proving ground in which to deepen understanding of cognition, with new models that, for example, accurately represent the beliefs of others or have the richness and capacity of human memory.

Major advances will require a virtuous cycle between data and models, experimentalists and theorists. Spatial arrangements in 100 College will encourage such feedback loops. The computational sciences will be situated on a middle floor between the psychological sciences above and the biological sciences below a physical reminder of their central role in bridging the Institutes mission. To foster intellectual collisions, the middle floor will also offer flexible shared spaces conducive to interaction, among them a large common room with sweeping views, whiteboards, and refreshments, hoteling offices for researchers visiting from across campus and across the world, and attractive forums for workshops, symposia, and events.

These communal spaces will be complemented by purpose-built facilities equipped with the latest neuroscientific tools. In a welcoming and inspiring atmosphere on the ground floor, for example, the Institute will house state-of-the-art technologiesfor studying the human brain in action. Designed for exploration and discovery, the new facility will enable big research ideas, hands-on educational opportunities, and alumni and community engagement.

In these and other ways, the Wu Tsai Institute represents an opportunity to transform how Yale and the academy pursue inquiries of great breadth and complexity.

The power of the idea behind the Institute is in enabling Yales researchers to find new intellectual connections and then providing resources to pursue questions at these intersections, said Daniel Coln-Ramos, Yale neuroscientist and cell biologist and executive committee member. Like a synaptic cleft between neurons, an axon between cortical areas, or the open air between brains in a social world, subfields of neuroscience vary in the distance that will need to be traveled. But as with messages delivered by chemicals, electrical pulses, or verbal speech, conversation, collaboration, and discovery narrow these distances and produce larger networks with greater knowledge and capabilities. Filling the space between these disciplines will allow us to answer the biggest whys and the grandest hows.

Expanding the number of students and postdocs encourages the multidisciplinary work that will be an Institute hallmark and also allows Yale to reinforce its commitment to diversity and excellence across the sciences. Students and postdocs are one of the best ways to bridge research areas, said Coln-Ramos. Because theyre conducting and shaping their labs research day to day, and because theyre in the midst of building new skills, they are often the ones to seek out collaborators.

The Institutes mission and organization stand to deepen connections throughout Yale.

The formation of the Wu Tsai Institute will lead to a new era of partnership between the School of Medicine and Faculty of Arts and Sciences, said Nancy J. Brown, M.D., dean of the School of Medicine. We cannot solve the pressing questions in neuroscience without interdisciplinary approaches. The Institute can serve as a model for collaborations in other areas.

Indeed, the Institute will yield collaborative opportunities and benefit from scholarship far beyond fields traditionally involved in neuroscience research.

The relation between mind and brain is among the deepest and most profound questions that we face, said Tamar Gendler, philosopher and dean of the Faculty of Arts and Sciences. To understand it, we must draw on methods and insights from across disciplines and approaches: aesthetic, ethical, social, biological, physical, and technical. I am excited to help realize the bold and imaginative promise of the Wu Tsai Institute, with key engagement from fellow FAS leaders, including deans Alan Gerber in the social sciences and Jeffrey Brock in the natural sciences and engineering, and department chairs from across the academic divisions.

Alongside the research mission and integral to it the Institute will serve Yales teaching mission. In addition to providing for new postdoctoral fellows, it will expand graduate education in neuroscience through support of the well-established and highly successful Interdepartmental Neuroscience Program, as well as other top Ph.D. programs across the university. At the undergraduate level, it will fund summer fellowships and year-round research opportunities for students in Yales fast-growing neuroscience major and related majors. Established in 2017 by psychologist and now Yale College Dean Marvin Chun, the neuroscience major has more than 80 students. The Institute will help prepare them for graduate and professional school, and for empirical, evidence-based decision-making regardless of career path.

The Wu Tsai Institute is a marvelous expression of our ambitions in neuroscience, in data science, and in engineering, and it will be a major instrument of their fulfillment, said Brock, dean of science and dean of the School of Engineering & Applied Science. It represents the bold, creative organizational thinking that will serve our faculty and students well as they strive to advance knowledge and make the breakthroughs that benefit all humankind. We are grateful to Joe Tsai and Clara Wu Tsai for their vision and their confidence as we at Yale aim to push scientific boundaries.

For more information about the Wu Tsai Institute and to sign up to receive updates, please visit the Institute website at wti.yale.edu.

Read the original here:
At Yale, new neuroscience institute to unravel the mysteries of cognition - Yale News

Neuroscientist David Sulzer To Release Debut Book MUSIC, MATH, AND MIND: THE PHYSICS AND NEUROSCIENCE OF MUSIC – Broadway World

David Sulzer's debut book, Music, Math, and Mind, offers a lively exploration of the mathematics, physics, and neuroscience that underlie music in a way that readers without scientific background can follow.

Dr. Sulzer, also known in the musical world as Dave Soldier, explains why the perception of music encompasses the physics of sound, the functions of the ear and deep-brain auditory pathways, and the physiology of emotion. He delves into topics such as the math by which musical scales, rhythms, tuning, and harmonies are derived, from the days of Pythagoras to technological manipulation of sound waves. Sulzer makes accessible a vast range of material-styles from around the world to canonical composers to hip-hop, the history of experimental music, and animal music by songbirds, cetaceans, bats, and insects.

From David Sulzer:

"Musicians and music lovers have innate curiosity about what they do and love, but essential questions that underlie every style of music aren't taught in classes, textbooks, or in pop science books. For example, why are there musical scales, what does it mean when something is out-of-tune, do other animals hear differently than we do, why are sounds different from each other, and how do we know it? These topics have been examined for thousands of years, but the math, physics and biology is intimidating to non-specialists. With this book and a bit of patience, anyone with grade school level multiplication and division can understand these questions and develop a basis for more profound understanding of what it means to engage in art."

David Sulzer is a professor in the Departments of Psychiatry, Neurology, and Pharmacology at Columbia University Medical Center. His laboratory has made important contributions to the study of brain mechanisms involved in autism, Parkinson's disease, drug addiction, and learning and memory. In his alter ego, Dave Soldier, he is a composer, performer, and producer who has worked with many major figures in the classical, jazz, and pop worlds, appearing on over one hundred records. Some of his projects bridge music and neuroscience, including the Thai Elephant Orchestra (an orchestra of fourteen elephants in Northern Thailand), and the Brainwave Music Project, which uses EEGs of brain activity to create compositions.

Some of the questions answered in Music, Math, and Mind:

How are emotions carried by music?How does the brain understand what it is listening to?How can we measure music? How fast, long and tall is it?What does it mean for sounds to be in or out of tune?How might a musician use math to come up with new ideas?Is there a mathematical definition of noise and consonance?How do we associate music with time, place, and dreams?Do other animals perceive sound and music like we do?

Music, Math, and Mind: The Physics and Neuroscience of MusicBy David SulzerColumbia University PressPub Date: April 27, 2021304 pagesHardcover $120.00 / 93.00 (978-0-231-19378-8)Paperback $28.00 / 22.00 (978-0-231-19379-5)E-book $27.99 / 22.00 (978-0-231-55050-5)

Read more here:
Neuroscientist David Sulzer To Release Debut Book MUSIC, MATH, AND MIND: THE PHYSICS AND NEUROSCIENCE OF MUSIC - Broadway World